Avidity Biosciences Stock News

Avidity Biosciences, Inc. (NASDAQ:RNA)’s share price shot up 6.6% during mid-day trading on Monday after SVB Leerink raised their price target on the stock from $36.00 to $53.00. SVB Leerink currently has an outperform rating on the stock. Avidity Biosciences traded as high as $26.02 and last traded at $25.98. 1,505 shares were traded during […]

Avidity Biosciences (NASDAQ:RNA)s stock had its buy rating reiterated by equities researchers at Wells Fargo & Company in a report issued on Friday, TipRanks reports. They presently have a $59.00 price objective on the biotechnology companys stock. Wells Fargo & Companys target price suggests a potential upside of 142.10% from the companys previous close. Several []

Avidity Biosciences (NASDAQ:RNA) had its target price increased by equities researchers at SVB Leerink from $36.00 to $53.00 in a research report issued to clients and investors on Friday, Stock Target Advisor reports. The firm presently has an outperform rating on the biotechnology companys stock. SVB Leerinks target price points to a potential upside of []

Avidity had its IPO on June 12, 2020. It is developing a new class of therapeutics, AOCs.

Nuveen Asset Management LLC grew its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA) by 22.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,060 shares of the biotechnology companys stock after buying an additional 21,804 shares during the period. Nuveen []

Avidity Biosciences, Inc. (NASDAQ:RNA) has been given a consensus rating of “Buy” by the six research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that […]

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -7.94% and 44.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LA JOLLA, Calif. , Aug. 31, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleo

LA JOLLA, Calif., Aug. 16, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucle

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 9.09% and 73.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LA JOLLA, Calif., Aug. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleot

LA JOLLA, Calif., Aug. 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucle

The FDA has signed off Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). Myotonic dystrophy is characterized by progressive

LA JOLLA, Calif., May 12, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucl